Mental health

Field Trip Health & Wellness Ltd. Announces Launch of Online Therapy

Retrieved on: 
Thursday, January 12, 2023

TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSX-V: FTHW) ("Field Trip" or the “Company”), a global leader in the delivery of psychedelic therapies, today launched Field Trip Online Therapy, a unique approach to psychotherapy that leverages contemporary talk therapy, integrative wellness tools and insights derived from being one of the largest global providers of psychedelic-assisted therapies.

Key Points: 
  • TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSX-V: FTHW) ("Field Trip" or the “Company”), a global leader in the delivery of psychedelic therapies, today launched Field Trip Online Therapy, a unique approach to psychotherapy that leverages contemporary talk therapy, integrative wellness tools and insights derived from being one of the largest global providers of psychedelic-assisted therapies.
  • “We are delivering unparalleled mental health results for people who complete our ketamine-assisted therapy,” said Ronan Levy, Chairman and CEO of Field Trip.
  • That is why I’m thrilled to introduce our Field Trip Online Therapy program.
  • Field Trip Online Therapy is now available in New York with plans to roll out to additional states throughout 2023.

PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

Retrieved on: 
Wednesday, January 11, 2023

TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today provided an update for its clinical development programs and milestones for 2023 with KETARX™ (racemic ketamine) as a potential treatment for mental health, neurological and pain disorders.

Key Points: 
  • Of the three forms of ketamine, only racemic ketamine and S-ketamine products have been approved by FDA.
  • The Company recently completed the development of the microneedle patch system for the intradermal delivery of sustained low-dose ketamine.
  • This milestone has enabled progression toward process validation and the manufacturing of cGMP clinical materials to support ongoing clinical development.
  • Upon completion of the study, PharmaTher aims to seek guidance from the FDA to determine the final clinical development plan.

Sprout Social Named to Glassdoor’s 2023 Best Places to Work List for the Fourth Consecutive Year

Retrieved on: 
Wednesday, January 11, 2023

CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Sprout Social , an industry-leading provider of cloud-based social media management software, has been named one of the best places to work in 2023 by Glassdoor’s Employees’ Choice Award in the US small and medium company category.

Key Points: 
  • CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Sprout Social , an industry-leading provider of cloud-based social media management software, has been named one of the best places to work in 2023 by Glassdoor’s Employees’ Choice Award in the US small and medium company category.
  • “At Sprout, we believe our best is always ahead of us and our continued placement on this list speaks to that ethos.
  • I sincerely congratulate all of the Best Places to Work winners.”
    Glassdoor’s Best Places to Work winners were determined using company reviews shared by US-based employees between October 19, 2021 and October 17, 2022.
  • For the complete list of the Glassdoor Best Places to Work winners in 2023, please visit: gldr.co/BPTWSMB

R3 Continuum Named One of the Nation’s Best and Brightest Companies to Work For in 2022

Retrieved on: 
Tuesday, January 10, 2023

Each department or team conducted a series of meetings to discuss our mission, purpose, core values and long-term goals.

Key Points: 
  • Each department or team conducted a series of meetings to discuss our mission, purpose, core values and long-term goals.
  • Another key component of a remarkable company is a culture that is committed to making a positive community impact.
  • Throughout 2022, R3c supported workplaces in the aftermath of many disruptive events, notably the Buffalo, Uvalde, and recent Colorado Springs shootings.
  • The company continued to support not only its clients, but its own workforce throughout the challenges of 2022 and will continue to do the same in the new year.

Heart to Heart CPR Raises Awareness of Ontario's NEW Workplace Naloxone Requirements Effective June 1, 2023

Retrieved on: 
Tuesday, January 10, 2023

For up to two years, Ontario will provide one free nasal spray naloxone kit per workplace and free naloxone training for up to two workers per workplace.

Key Points: 
  • For up to two years, Ontario will provide one free nasal spray naloxone kit per workplace and free naloxone training for up to two workers per workplace.
  • Training requirements must include how to recognize opioid poisoning, how to administer naloxone , and being acquainted with any hazards related to the administration of naloxone .
  • Oftentimes naloxone alone is not enough to assist a worker who is unconscious and experiencing opioid poisoning in the workplace.
  • To conclude, not all employers have to comply with the OHSA requirements to provide naloxone in the workplace.

Irwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical Companies in the US

Retrieved on: 
Tuesday, January 10, 2023

The partnership will bring together Braxia’s expertise, track record of leadership in innovative mental health treatments and current comprehensive clinical research capabilities to 12 Emergence clinics in 5 US states.

Key Points: 
  • The partnership will bring together Braxia’s expertise, track record of leadership in innovative mental health treatments and current comprehensive clinical research capabilities to 12 Emergence clinics in 5 US states.
  • Under the terms of the LOI, Irwin will invest up to $2 million over the next 12 months to launch initial clinical research services beginning with at least 5 clinics in Florida.
  • Irwin and Braxia’s partnership will create a leading mental health focused clinical research platform designed to streamline and accelerate the process of in-human clinical development of new therapies, including seamless patient recruitment through to FDA application.
  • Having an outstanding reputation for scientific expertise, quality clinical research in depression and other mental health disorders areas that will enable us to further develop our US clinical footprint."

Neuronetics Settles Litigation Against BrainsWay

Retrieved on: 
Tuesday, January 10, 2023

MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it has settled the litigation filed in the District of Delaware against BrainsWay Ltd. and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law.

Key Points: 
  • MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it has settled the litigation filed in the District of Delaware against BrainsWay Ltd. and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law.
  • Under the terms of the settlement, BrainsWay agreed to stop the use of the efficacy data for the treatment of anxious depression with NeuroStar® Advanced Therapy for Mental Health that was at issue in the Complaint filed by Neuronetics.
  • “As I said at the outset of this litigation, Neuronetics will vigorously defend our data and the efficacy of NeuroStar® Advanced Therapy for Mental Health,” said Keith J. Sullivan, President and Chief Executive Officer.
  • The parties have agreed to keep the additional terms of the settlement agreement confidential.

The Scotts Miracle-Gro Foundation Welcomes Applications for 2023 GroMoreGood Grassroots Grant with KidsGardening to Connect Children to Benefits of Gardening and Greenspaces

Retrieved on: 
Monday, January 9, 2023

In the past years, ScottsMiracle-Gro and KidsGardening have seen firsthand how communities are using gardening to provide relief for those in need.

Key Points: 
  • In the past years, ScottsMiracle-Gro and KidsGardening have seen firsthand how communities are using gardening to provide relief for those in need.
  • "2023 marks KidsGardening’s 41st year and our second decade working alongside The Scotts Miracle-Gro Foundation.
  • Yet, now more than ever, kids and their communities need gardens and greenspaces," said Em Shipman, executive director of KidsGardening.
  • It’s truly an honor to support this work.”
    The GroMoreGood Grassroots Grant application will be open until February 10, 2023.

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Retrieved on: 
Monday, January 9, 2023

GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.

Key Points: 
  • GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.
  • Initiation of a GRX-917 efficacy study is anticipated in H1 2023 with results expected in 2024.
  • NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.
  • The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and pharmacokinetic profile of single and multiple ascending doses of orally administered GRX-917.

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Retrieved on: 
Monday, January 9, 2023

RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.

Key Points: 
  • RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.
  • In this first-in-human, Phase 1 study, RE104 was shown to be safe and well tolerated, with no serious or severe adverse events.
  • The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving placebo.
  • While completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee (SRC), Reunion has continued with dose escalation and initiated a fifth cohort.